Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

The current study aims to explore the potential advantages of anti-cancer therapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced thyroid cancer who have undergone conventional therapy in the past or unresectable patients .

Trial Details

NCT ID
NCT06482086
Phase
PHASE2
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • Anlotinib
  • Lenvatinib
  • Sorafenib
  • Donafenib
  • Everolimus
  • Apatinib
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • 1\. Adult participants who have either been initially diagnosed with locally advanced thyroid cancer or have experienced persistent or recurrent th…
  • Papillary thyroid carcinoma (PTC)
  • Follicular thyroid carcinoma (FTC)
  • Medullary thyroid carcinoma (MTC)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →